Enrolling by invitationPHASE1, PHASE2NCT07221565

Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

Studying Systemic lupus erythematosus

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Truway Health, Inc.
Principal Investigator
Gavin Solomon, President & CEO
Truway Health, Inc.
Intervention
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR)(device)
Enrollment
120 enrolled
Eligibility
All sexes
Timeline
20252034

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07221565 on ClinicalTrials.gov

Other trials for Systemic lupus erythematosus

Additional recruiting or active studies for the same condition.

See all trials for Systemic lupus erythematosus

← Back to all trials